Vivos Therapeutics, Inc. (VVOS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Vivos Therapeutics, Inc. reported revenue of $17.44M, up 16.0% from the prior year. The company ran a net loss, with a net margin of -121.4% and a gross margin of 60.4%. It held $25.15M in total assets against $26.70M in total liabilities.
Key ratios (FY2025)
60.4%
Gross margin
-114.1%
Operating margin
-121.4%
Net margin
+16.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.44M | $15.03M | $13.80M | $16.02M | $16.89M | $13.07M | $11.39M | — |
| Cost of Revenue | $6.90M | $6.01M | $5.53M | — | — | — | — | — |
| Gross Profit | $10.54M | $9.02M | $8.27M | $10.02M | $12.60M | $10.41M | $8.66M | — |
| Operating Income | -$19.89M | -$11.17M | -$17.30M | -$25.03M | -$20.38M | -$12.04M | -$10.58M | — |
| Net Income | -$21.17M | -$11.14M | -$13.58M | -$23.84M | -$20.29M | -$12.06M | -$10.75M | — |
| EPS (Diluted) | $-2.07 | $-2.22 | $-11.14 | $-25.90 | $-0.96 | — | — | — |
| Total Assets | $25.15M | $15.28M | $10.73M | $13.72M | $33.69M | $25.33M | $7.55M | — |
| Total Liabilities | $26.70M | $7.33M | $10.32M | $8.92M | $8.15M | $8.41M | $9.18M | — |
| Shareholders' Equity | -$1.49M | $7.95M | $411.0K | $4.80M | $25.54M | $16.92M | -$2.94M | $4.83M |
| Cash & Equivalents | $2.03M | $6.26M | $1.64M | $3.52M | $24.03M | $18.21M | $469.4K | — |
| Operating Cash Flow | -$15.26M | -$12.69M | -$11.95M | -$19.59M | -$15.73M | -$5.68M | -$5.34M | — |
| Capital Expenditures | $2.34M | $568.0K | $803.0K | $924.0K | $2.40M | $120.0K | $175.6K | — |
| Shares Outstanding | 9.29M | 5.89M | 1.83M | 920.6K | 23.01M | 18.21M | 12.44M | — |